All of the active B12 group reporting showed reduction in severity of nutrition symptoms ranging from 31% to 70%, while the placebo controls reported either no change or a worsening of and and children symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nutrition and and nasal congestion children and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. nutrition The FDA panel acknowledged the safety of the treatment. The panel seemed and to be in agreement that the statistics indicated a significant reduction in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen Anibarro, MD, studied five children with asthma with metabisulfite children intolerance confirmed by oral nutrition challenge testing. The test was repeated after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6

Studies indicate that ingested oral cyanocobalamin tablets are ineffective in the treatment of allergic disease, perhaps because once ingested, they and are directly metabolized in the liver. When B12 is delivered via injection or lozenge it passes throughout the bloodstream before arriving at the liver. It is during children this first pass in its native form that it is believed to exert its therapeutic effect. CLINICAL RESEARCH: "The World Health Organization (WHO) recognizes allergic rhinitis (hay fever), sinusitis, asthma,...conjunctivitis, urticaria, nutrition eczema, and dermatitis (contact children and atopic)...allergic and migraine headache...as diseases in which IgE-mediated nutrition allergy may be involved."1 In 1988, asthma and allergic rhinitis subjects were treated and with B12. Total IgE, specific IgE and pulmonary lung functions were taken at days 45, 150 and 180 from baseline. Eight of the 9 subjects had reduced IgE. 2 In 1989 open label studies at two sites in Riverside children County, CA in 1989. Sixteen of the 17 subjects had lowered IgE levels from Day 0 to Day 30.3